Logo

American Heart Association

  2
  0


Final ID: Su3065

Prediction of Incident Atrial Fibrillation Using Handheld Single-Lead Electrocardiograms from the VITAL-AF Trial

Abstract Body (Do not enter title and authors here): Background: Deep learning of 12-lead electrocardiograms (ECGs) can estimate future atrial fibrillation (AF) risk. Whether these models can be applied to single-lead ECGs (1L ECGs) from wearable or handheld devices is unknown.

Aim: To apply a previously published deep learning model to estimate 2-year incident AF risk using handheld 1L ECGs obtained prospectively in a large AF screening trial.

Methods: In the VITAL-AF trial (NCT03515057), over 16,000 primary care patients aged ≥65 years underwent AF screening with handheld 1L ECG. We applied our published deep learning model (ECG-AI) derived using single leads of over 450,000 standard 12-lead ECGs external to the VITAL-AF study (1L ECG-AI). We compared the performance of 1L ECG-AI to the validated CHARGE-AF clinical risk score and calculated net reclassification indices.

Results: Among 15,694 individuals enrolled in VITAL-AF and without prevalent AF (age 74±7 years, 9,104 [58%] women), 1L ECG-AI discriminated 2-year incident AF (area under receiver operating characteristic curve [AUROC] 0.666 [95% CI 0.603-0.721]). With addition of age and sex (1L ECG-AI AS), 2-year AF discrimination (0.695 [0.637-0.742]) was comparable to the 11-component CHARGE-AF clinical risk score (0.679 [0.625-0.729]). Two-year AF incidence was markedly higher with 1L ECG-AI AS in the top 5% (8.0% [5.7-10.2]) vs bottom 5% (0.89% [0.23-0.55]). At a threshold of ≥3% estimated 2-year AF risk, AF incidence was progressively higher among patients at high risk according to neither model (1.5% [1.2-1.8]), one model (1L ECG-AI: 3.3% [2.3-4.2]; CHARGE-AF 3.4% [2.2-4.6]), and both models (5.8% [5.0-6.5]), implying that clinical risk and ECG-AI signals are complementary (Figure). Compared to screening all individuals at the guideline-based threshold of ≥65 years, 1L ECG-AI AS resulted in favorable net reclassification improvement (0.27 [0.22-0.32]).

Conclusion: An ECG-AI algorithm developed using single leads of a 12-lead ECG combined with age and sex can discriminate AF risk using real-world handheld 1L ECGs with comparable performance to the CHARGE-AF score. 1L ECG-AI signals complement clinical risk factors. ECG-AI applied to 1L ECG may increase the reach and efficiency of AF screening.
  • Khurshid, Shaan  ( Massachusetts General Hospital , Boston , Massachusetts , United States )
  • Atlas, Steven  ( Massachusetts General Hospital , Boston , Massachusetts , United States )
  • Maddah, Mahnaz  ( Broad Institute , Cambridge , Massachusetts , United States )
  • Singer, Daniel  ( Massachusetts General Hospital , Wellesley , Massachusetts , United States )
  • Ellinor, Patrick  ( Massachusetts General Hospital , Boston , Massachusetts , United States )
  • Friedman, Sam  ( Broad Institute of MIT and Harvard , Cambridge , Massachusetts , United States )
  • Al-alusi, Mostafa  ( Massachusetts General Hospital , Boston , Massachusetts , United States )
  • Kany, Shinwan  ( Broad Institute , Cambridge , Massachusetts , United States )
  • Anderson, Christopher  ( Broad Institute of MIT and Harvard , Cambridge , Massachusetts , United States )
  • Ho, Jennifer  ( Harvard Medical School , Newton , Massachusetts , United States )
  • Mcmanus, David  ( UMMS , Worcester , Massachusetts , United States )
  • Ashburner, Jeffrey  ( Massachusetts General Hospital , Boston , Massachusetts , United States )
  • Lubitz, Steven  ( Novartis , Cambridge , Massachusetts , United States )
  • Author Disclosures:
    Shaan Khurshid: DO NOT have relevant financial relationships | Steven Atlas: DO have relevant financial relationships ; Researcher:Bristol Myers Squibb:Active (exists now) ; Consultant:Premier:Past (completed) ; Consultant:Fitbit (Google):Past (completed) ; Consultant:Boehringer Ingelheim:Past (completed) ; Consultant:Pfizer:Past (completed) ; Consultant:Bristol Myers Squibb:Past (completed) | Mahnaz Maddah: DO NOT have relevant financial relationships | Daniel Singer: No Answer | Patrick Ellinor: DO have relevant financial relationships ; Research Funding (PI or named investigator):Bayer AG:Active (exists now) ; Research Funding (PI or named investigator):Pfizer:Active (exists now) ; Research Funding (PI or named investigator):BMS:Active (exists now) ; Research Funding (PI or named investigator):Novo Nordisk:Active (exists now) ; Consultant:Bayer AG:Active (exists now) | Sam Friedman: DO NOT have relevant financial relationships | Mostafa Al-Alusi: DO NOT have relevant financial relationships | Shinwan Kany: DO NOT have relevant financial relationships | Christopher Anderson: No Answer | Jennifer Ho: DO have relevant financial relationships ; Individual Stocks/Stock Options:Pfizer:Active (exists now) | David McManus: DO have relevant financial relationships ; Research Funding (PI or named investigator):Bristol Myers Squibb:Past (completed) ; Other (please indicate in the box next to the company name):NONE:Past (completed) ; Other (please indicate in the box next to the company name):NONE:Past (completed) ; Other (please indicate in the box next to the company name):NONE:Past (completed) ; Other (please indicate in the box next to the company name):NONE:Past (completed) ; Other (please indicate in the box next to the company name):NONE:Past (completed) ; Other (please indicate in the box next to the company name):NONE:Past (completed) ; Consultant:Avania:Active (exists now) ; Consultant:NAMSA:Active (exists now) ; Consultant:Fitbit:Past (completed) ; Consultant:Heart Rhythm Society:Past (completed) ; Consultant:Bristol Myers Squibb/Pfizer:Past (completed) ; Research Funding (PI or named investigator):Boehringer Ingelheim:Past (completed) ; Research Funding (PI or named investigator):Pfizer:Past (completed) ; Consultant:Flexcon:Past (completed) | Jeffrey Ashburner: DO NOT have relevant financial relationships | Steven Lubitz: DO have relevant financial relationships ; Employee:Novartis:Active (exists now)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Seeing Beyond the Beat: Innovations in Cardiovascular Imaging and Risk Evaluation

Sunday, 11/17/2024 , 03:15PM - 04:15PM

Abstract Poster Session

More abstracts on this topic:
Age-Related Differences in Aortic Valve Calcium Progression and the Risk for Aortic Stenosis: Multi-Ethnic Study of Atherosclerosis

Marrero Natalie, Thanassoulis George, Rotter Jerome, Blaha Michael, Whelton Seamus, Jha Kunal, Grant Jelani, Razavi Alexander, Budoff Matthew, Shah Sanjiv, Blumenthal Roger, Post Wendy, Shaw Leslee

12,13-diHOME Attenuates Pro-Arrhythmic Effect of High-Fat Diet

Buck Benjamin, Baer Lisa, Deschenes Isabelle, Chinthalapudi Krishna, Gallego-perez Daniel, Stanford Kristin, Hund Thomas, Areiza Natalia, Xu Xianyao, Elliott Austin, Wan Xiaoping, Nassal Drew, Lane Cemantha, Nirengi Shinsuke, James Natasha Maria

More abstracts from these authors:
A Deep Learning Digital Biomarker for Mitral Valve Prolapse using Echocardiogram Videos

Al-alusi Mostafa, Khurshid Shaan, Sanborn Danita, Picard Michael, Ho Jennifer, Maddah Mahnaz, Ellinor Patrick, Lau Emily, Small Aeron, Reeder Christopher, Shnitzer Dery Tal, Andrews Carl, Kany Shinwan, Ramo Joel, Haimovich Julian

Targeted Atrial Fibrillation Screening in Older Adults: A Secondary Analysis of the VITAL-AF Trial

Shah Sachin, Singer Daniel, Iyer Jay, Agha Leila, Chang Yuchiao, Atlas Steven, Ashburner Jeffrey, Mcmanus David, Ellinor Patrick, Lubitz Steven

You have to be authorized to contact abstract author. Please, Login
Not Available